CANON Trial Update

Phase I/II CANON (CAvatak in NON muscle invasive bladder cancer) preliminary data

Observed:
Tumour Response (Pre and post treatment cystoscopy): Complete clinical response (confirmed by histopathology)

Conclusions
CANON Phase I trial: Proof of concept viral targeting, replication and tumour cell death following a single or multiple intravesicular administrations of CVA21 was achieved in patients from monotherapy Cohorts 1, 2 and 3 and combination Cohorts 1, and 2. • Clinical activity of CVA21 demonstrated by complete tumour response, viral replication (infectious virus increases in urine) and notable signs of viral-induced tumor inflammation. • No evidence of systemic spread of CVA21 or development of serum neutralizing antibody. • To date intravesicular administration of CVA21 has been generally well tolerated with no Grade 2, 3 or 4 product-related AE’s. • The observed tumor targeting and viral replication is likely to provide a strong signal in generating both a strong local and systemic anti-tumour immune response.

http://www.viralytics.com/wp-content/uploads/2016/03/EAU-2016-CANON-poster-FINAL.pdf